About bristol myers squibb co. - BMY
BMY At a Glance
| Phone | 1-609-252-4621 | Revenue | 48.30B | |
| Industry | Pharmaceuticals: Major | Net Income | -8,948,000,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 7.319% | |
| Fiscal Year-end | 12 / 2025 | Employees | 34,100 | |
| View SEC Filings |
BMY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.374 |
| Price to Book Ratio | 7.025 |
| Price to Cash Flow Ratio | 7.548 |
| Enterprise Value to EBITDA | 8.029 |
| Enterprise Value to Sales | 3.21 |
| Total Debt to Enterprise Value | 0.33 |
BMY Efficiency
| Revenue/Employee | 1,416,422.287 |
| Income Per Employee | -262,404.692 |
| Receivables Turnover | 3.349 |
| Total Asset Turnover | 0.514 |
BMY Liquidity
| Current Ratio | 1.253 |
| Quick Ratio | 1.145 |
| Cash Ratio | 0.457 |
BMY Profitability
| Gross Margin | 56.795 |
| Operating Margin | 19.996 |
| Pretax Margin | -17.348 |
| Net Margin | -18.526 |
| Return on Assets | -9.531 |
| Return on Equity | -39.104 |
| Return on Total Capital | -13.249 |
| Return on Invested Capital | -13.464 |
BMY Capital Structure
| Total Debt to Total Equity | 313.437 |
| Total Debt to Total Capital | 75.813 |
| Total Debt to Total Assets | 55.29 |
| Long-Term Debt to Equity | 299.804 |
| Long-Term Debt to Total Capital | 72.515 |
Bristol Myers Squibb Co. in the News
Bristol Myers to buy RayzeBio for about $4.1B
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
Bristol Myers to buy Karuna Therapeutics for $14B
Karuna’s crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.
Coalition calls on Congress to repeal Biden's prescription drug price controls
More than 40 groups have signed onto a letter asking Congress to end the prescription drug price control scheme included in the Inflation Reduction Act.
Western drugmakers are still providing medicines to Russia
Western health care companies continue supplying medicine, vaccines and medical equipment to Russia.
Drugmakers raised prices by 6.6% on average early this year
Drugmakers raised prices an average of 6.6% at the start of 2022.
Biden pushes Congress to allow Medicare to negotiate drug prices
President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected to push Congress to pass legislation that would allow Medicare to negotiate drug prices for millions of Americans.
Stock futures trade mixed ahead of Fed decision
U.S. equity futures were pointing lower ahead of Wednesday's opening bell on Wall Street.
Warren Buffett's Berkshire Hathaway shakes up investment holdings
Warren Buffett's Berkshire Hathaway cut back on financial, energy and drug stocks but beefed up its grocery and wireless holdings while adding an insurer.